AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03043989 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cabazitaxel
Description: 6 infusions of Cabazitaxel with 18 doses clarithromycin
Study NCT03043989 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clarithromycin
Description: 18 doses of clarithromycin with either Docetaxel or Cabazitaxel
Study NCT04232072 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group ESPB
Description: A dose of 100 mg tramadol intravenously will be performed to all patients 30 min before the end of the surgery for postoperative analgesia. At the end of the surgery, local anesthetic infiltration will be perfomed around the port entrance sites by the surgical team to the all patients. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit at the postoperative period.
Study NCT04232072 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group Ibuprofen
Description: A dose of 100 mg tramadol intravenously will be performed to all patients 30 min before the end of the surgery for postoperative analgesia. At the end of the surgery, local anesthetic infiltration will be perfomed around the port entrance sites by the surgical team to the all patients. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit at the postoperative period. In Group Ibuprofen, patients will be administered ibuprofen 800 mgr IV every 8 hours in the postoperative period.
Study NCT01826487 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ataluren
Description: Ataluren will be administered as per the dose and schedule specified in the arm.
Study NCT01826487 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered as per the schedule specified in the arm.
Study NCT04566354 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Repeated 30-s sprint exercise
Description: Analyze of Interleukin-6 concentration before and after repeated 30-s sprint exercise
Study NCT01519960 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a [Pegasys]
Description: Body surface area adapted doses of 45-180 mcg subcutaneously weekly for 48 weeks, Weeks 1- 48
Study NCT01519960 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a [Pegasys]
Description: Body surface area adapted doses of 45-180 mcg subcutaneously weekly for 48 weeks, after Week 48 for Group B patients who have not experienced HBeAg seroconversion
Study NCT01266876 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alirocumab
Description: Alirocumab two SC injections in the abdomen only.
Study NCT01266876 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo two SC injections in the abdomen only.
Study NCT00315640 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anecortave Acetate Sterile Suspension, 6 mg/mL
Description: One 0.5 mL anterior juxtascleral depot (AJD) injection in the study eye
Study NCT00315640 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anecortave Acetate Suspension Depot, 30 mg/mL
Description: One 0.5 mL anterior juxtascleral depot (AJD) injection in the study eye
Study NCT00315640 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anecortave Acetate Sterile Suspension, 60 mg/mL
Description: One 0.5 mL anterior juxtascleral depot (AJD) injection in the study eye
Study NCT00315640 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Anecortave Acetate Vehicle
Description: One 0.5 mL anterior juxtascleral depot (AJD) injection in the study eye
Study NCT01077310 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vivitrol- Intramuscular naltrexone (depot-formulation)
Description: Subjects in this arm will receive monthly intramuscular gluteal injections of depot naltrexone 380mg (VIVITROL) for 6 months. The 1st injection will be administered prior to release from prison or jail.
Study NCT00742118 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Colic biopsies
Description: colic biopsies and analysis
Study NCT00742118 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Colic biopsies
Description: colic biopsies and analysis
Study NCT02011477 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Neural Glide
Description: This technique involves two movements, throughout several joints to glide the nerves. The subject sit on a couch with the right lower limb extended and the left lower limb flexed. The therapist will take the subject's head by putting his hands on the suboccipital and front region. In the initial movement, performe craniocervical flexion in the subject, while he helped with his right elbow to rectify the dorsal spine of the subject; at the same time, the subject performed dorsiflexion of the right ankle. In the final movement, the subject must increase thoracic kyphosis at the same time as performing plantarflexion in the right ankle; also, the therapist performed craniocervical extension in the subject
Study NCT02011477 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Neural Glide
Description: This technique involves two movements, throughout several joints to glide the nerves. The subject sit on a couch with the right lower limb extended and the left lower limb flexed. The therapist will take the subject's head by putting his hands on the suboccipital and front region. In the initial movement, performe craniocervical flexion in the subject, while he helped with his right elbow to rectify the dorsal spine of the subject; at the same time, the subject performed dorsiflexion of the right ankle. In the final movement, the subject must increase thoracic kyphosis at the same time as performing plantarflexion in the right ankle; also, the therapist performed craniocervical extension in the subject
Study NCT02011477 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neural stretching
Description: In the start position, the subject was supine on a couch, with knees bent with the right leg above the left, and supported with the popliteal zone. Both hands were crossed over the chest. The therapist was on the subject´s side, with his knee below the subject's head, bringing stability. One hand was placed on the occipital, and the other hand was placed over the crossed hands of the subject
Study NCT02011477 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Neural stretching
Description: In the start position, the subject was supine on a couch, with knees bent with the right leg above the left, and supported with the popliteal zone. Both hands were crossed over the chest. The therapist was on the subject´s side, with his knee below the subject's head, bringing stability. One hand was placed on the occipital, and the other hand was placed over the crossed hands of the subject
Study NCT02623985 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sofia
Description: Patients who presented with sore throat will be performed throat swab and sent for Sofia for rapid test.
Study NCT02623985 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: QuickVue
Description: Patients who presented with sore throat will be performed throat swab and sent for QuickVue for rapid test.
Study NCT02623985 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Throat swab culture
Description: Patients who presented with sore throat will be performed throat swab and sent for throat swab culture for gold standard.
Study NCT02108912 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ESTT
Description: ESTT is early-standardized task-specific training is a treadmill and over ground gait protocol for gait recovery after stroke
Study NCT02108912 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional outpatient
Description: Traditional physical therapy includes standard of care for gait recovery after stroke such as pre-gait activities, standing balance activities, strengthening, walking with assistive devices.
Study NCT04274257 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Double-Blind Placebo
Description: The 4-week treatment period (four 375 mg/m2 doses at 1-week intervals) and subsequent 20-week follow-up period constitute one cycle of treatment.~In the double-blind period, one cycle of placebo will be administered. In the active drug period, one additional cycle (rituximab) will be administered.
Study NCT04274257 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Double-Blind Rituximab
Description: The 4-week treatment period (four 375 mg/m2 doses at 1-week intervals) and subsequent 20-week follow-up period constitute one cycle of treatment.~In the double-blind period, one cycle of rituximab will be administered. In the active drug period, one additional cycle (rituximab) will be administered.
Study NCT04290195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ziv-Aflibercept 25 MG/ML [Zaltrap]
Description: Intravitreal injection of 1.25 mg of ziv aflibercept in patients
Study NCT03633097 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture and Usual care
Description: patients after surgery receive usual care(Cnoxane Injection 40mg, Esomezol Capsule, Synerjet Semi Tablet and Ocoron Tablet) as well as acupuncture treatment as an adjunctive therapy
Study NCT03633097 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: patients after surgery receive usual care alone(Cnoxane Injection 40mg, Esomezol Capsule, Synerjet Semi Tablet and Ocoron Tablet)
Study NCT01017627 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Early anemia diagnosis and treatment
Description: Patients returning to the unit are immediately assessed and treated for anemia
Study NCT01017627 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: No change from normal routine
Description: Normal unit policy for labs and anemia treatment
Study NCT02473198 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exparel
Description: Prior to cementing of the prosthesis (minimum 20 minutes later), injection with mixture of 40 mL normal saline solution and 20mL 1.3% Exparel.
Study NCT02473198 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Femoral Nerve Block Bupivacaine
Description: The patient will then undergo an ultrasound guided femoral nerve block in the preoperative area with bupivacaine 0.25% 20 cc. All patients will undergo unilateral TKR using a medial parapatellar approach. Intraoperatively prior to cementing of the TKR, patients will also receive a local anesthetic injection of a mixture of 30cc 0.25% bupivicaine with epinephrine, 30mg of toradol and 10 mg of morphine sulfate into the posterior capsule of the knee joint.
Study NCT02473198 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toradol
Description: The patient will then undergo an ultrasound guided femoral nerve block in the preoperative area with bupivacaine 0.25% 20 cc. All patients will undergo unilateral TKR using a medial parapatellar approach. Intraoperatively prior to cementing of the TKR, patients will also receive a local anesthetic injection of a mixture of 30cc 0.25% bupivicaine with epinephrine, 30mg of toradol and 10 mg of morphine sulfate into the posterior capsule of the knee joint.
Study NCT02473198 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine Sulfate
Description: The patient will then undergo an ultrasound guided femoral nerve block in the preoperative area with bupivacaine 0.25% 20 cc. All patients will undergo unilateral TKR using a medial parapatellar approach. Intraoperatively prior to cementing of the TKR, patients will also receive a local anesthetic injection of a mixture of 30cc 0.25% bupivicaine with epinephrine, 30mg of toradol and 10 mg of morphine sulfate into the posterior capsule of the knee joint.
Study NCT01194063 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omega-3 fish oil lipid emulsion
Description: daily intravenous administration of Omegaven fish oil emulsion
Study NCT02293980 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-3795
Description: Oral administration
Study NCT02293980 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: IV infusion
Study NCT02293980 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: Oral administration
Study NCT02293980 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bezlutifan
Description: Oral administration
Study NCT03729726 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Future Foundation 2.0 PREIS Program
Description: The Future Foundation 2.0 PREIS intervention model uses a placed-based collective impact framework to provide a comprehensive intervention model, including: academic support and college and career readiness services, evidence-based social emotional learning instruction to strengthen protective factors and promote healthy transitions to adulthood, and trauma-informed, medically accurate, and age appropriate sexual health education. Moreover, the 2.0 PREIS program model features a unique student advocacy component designed to ensure that youth and their families receive the wraparound supports necessary for their students to remain on track for school success.
Study NCT04113785 — intervention group
Intervention type: DEVICE
Intervention: Klassic Knee System
Description: At present, all TKA available for surgeons to use are asymmetric where there is a distinct femoral and tibial component for the left knee and a distinct femoral and tibial component for the right knee. The Klassic knee system is a symmetrical knee implant, where the same femoral and same tibial component can be used for either the right or left knee
Study NCT03981692 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Consecutive dual task
Description: 8 weeks and 2 days per week, one session 45 min. Consecutive dual task creates the idea that it may provide more workable work without creating stress while doing secondary task during dual task.
Study NCT03981692 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Integrated dual task
Description: 8 weeks and 2 days per week, one session 45 min. Integrated dual task is a proven mode of work that has positive effects on geriatrics
Study NCT03161340 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rapamycin
Description: Patients will take Rapamycin 2 days before IVF until 15 days after IVF
Study NCT02501564 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen Sodium Codeine
Description: One tablet twice a day
Study NCT02501564 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One tablet twice a day
Study NCT00837876 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: 400 mg taken by mouth 1 time per day.
Study NCT00837876 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinb
Description: 150 mg taken by mouth 1 time per day.
Study NCT03675516 — intervention group
Intervention type: OTHER
Intervention: No specific intervention
Description: Usual care
Study NCT03412149 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mini Gastric Bypass
Description: Standardization of the techniques will be guaranteed:~1. Mini Gastric Bypass Arm~2. Roux en Y Gastric Bypass arm All patients will have intraoperative measurement of the whole length of bowel from Treitz ligament to the ileocecal junction (expected range 6-8 m).The common limb will be therefore about 2/3 of total small bowel length.
Study NCT03412149 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Roux en Y Gastric Bypass
Description: Standardization of the techniques will be guaranteed:~1. Mini Gastric Bypass Arm~2. Roux en Y Gastric Bypass arm All patients will have intraoperative measurement of the whole length of bowel from Treitz ligament to the ileocecal junction (expected range 6-8 m).The common limb will be therefore about 2/3 of total small bowel length.
Study NCT03460548 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Remogen
Description: instil 1 drop of the product in each eye, 4 times per day
Study NCT03460548 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cationorm
Description: instil 1 drop of the product in each eye, 4 times per day
Study NCT04284566 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TAU + multicomponent treatment FIBROWALK
Description: Group treatment protocol of 12 weekly 120 minute sessions. All sessions include the following ingredients (approx. in the same order):~* Pain neuroscience education (30 min.)~* Cognitive restructuring (30min.)~* Mindfulness techniques (30 min.)~* Physical exercise(30 min.)~* Treatment as Usual (TAU) Standard pharmacological treatment usually provided to patients with fibromyalgia.
Study NCT04284566 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual (TAU)
Description: Treatment-as-Usual (TAU) consisted of prescribing drugs adapted to the symptomatic profile of each patient. The patients were instructed to continue their baseline medical treatment with no change throughout the 3-month period. In Spain, some counselling about aerobic exercise adjusted to patients' physical limitations is usually provided by first-line clinicians and specialists, but pharmacotherapy it's still the dominant treatment option.
Study NCT02917720 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TKI discontinuation
Description: 2nd or 3rd TKI stop after pre-treatment with nilotinib.
Study NCT02917720 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nilotinib
Description: Pre-treatment with nilotinib 300 mg/bid for 2 years
Study NCT01048866 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Sugar-based lozenge flavoured to match the active treatment lozenge. Instructions were to suck one lozenge until gone, every 3-6 hours as needed for sore throat pain. The participant took nothing by mouth except study medication during the first two hours while at the site. For each re-dosing during the remaining time in the study, alcohol and caffeine-containing beverages (e.g., coffee, tea, hot chocolate, caffeinated soft drinks) were not consumed within 1 hour before the participant used a study medication lozenge.
Study NCT01048866 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: flurbiprofen
Description: Sugar-based, flavoured flurbiprofen 8.75 mg lozenge. Instructions were to suck one lozenge until gone, every 3-6 hours as needed for pain. The participant took nothing by mouth except study medication during the first two hours while at the site. For each re-dosing during the remaining time in the study, alcohol and caffeine-containing beverages (e.g., coffee, tea, hot chocolate, caffeinated soft drinks) were not consumed within 1 hour before the participant used a study medication lozenge.
Study NCT01048866 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acetaminophen 650mg
Description: Rescue medication to be taken as needed. Rescue medication was not blinded.
Study NCT01048866 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: acetaminophen 650mg
Description: Rescue medication to be taken as needed. Rescue medication was not blinded.
Study NCT00841399 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: E75 + GM-CSF vaccine
Description: Dose escalation scheme involving three patients each receiving injection of 100, 500, or 1,000 mcg E75 + GM-CSF monthly for 6 months. HLA-A2 and HLA-A3 status determined. HLA-A2+ and HLA-A3+ patients receive the vaccine; HLA-A2- and HLA-A3- enrolled to the control arm.
Study NCT01077310 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects in this arm will receive monthly intramuscular gluteal injections of placebo for 6 months. The 1st injection will be administered prior to release from prison or jail. Placebo will be provided by Alkermes pharmaceuticals, the manufacturer of VIVITROL. Placebo will be identical in shape and form to active drug.
Study NCT02306148 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Foot and ankle strengthening
Description: Group will be trained during 2 months at the university by a physiotherapist and at home with a training software for foot and ankle strengthening.
Study NCT01569061 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LCT-1000TM (Manufacturer: LiteCure)
Description: low level laser therapy (LLLT)
Study NCT01569061 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: LCT-1000TM (Manufacturer: LiteCure)
Description: low level laser therapy (LLLT) sham treatment
Study NCT01038726 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Training
Description: Aerobic exercise training program designed by the Cardiac Rehabilitation department
Study NCT01038726 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Training
Description: Based on cognitive training program Brain Fitness®
Study NCT01038726 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Flexibility Training
Description: Non-aerobic flexibility training program designed by the Cardiac Rehabilitation department
Study NCT01038726 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Educational Sessions
Description: DVD-based educational programs on history, art, and literature
Study NCT04432805 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Performing of lung ultrasound
Description: Performing of lung ultrasound at bedside in labor ward or in COVID unit
Study NCT04240093 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Activation (BA) Therapy
Description: 8 sessions of behavioral activation therapy
Study NCT04240093 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Substance Abuse and Health Navigation Counseling
Description: 2 standard substance abuse and health navigation counseling